Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Previous close
$4.46
−$0.09 · -1.98%
Regular session · ET · Market data may be delayed.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Day range
Current $4.46
52-week range
Current $4.46
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
11
Overpriced
Sentiment
73
Bullish
Risk
54
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Day range
Current $4.46
52-week range
Current $4.46
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.00
236.32% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.37M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM9.86M0.01%71.54B USD0.19%$256.61-2.88%
State Street SPDR S&P Biotech ETFXBI8.55M0.09%9.64B USD0.35%$140.18-2.73%
Vanguard Extended Market ETFVXF5.29M0.01%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO3.05M0.02%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO2.68M0.01%16.8B USD0.06%$103.76-2.76%
Fidelity Enhanced Small Cap ETFFESM2.38M0.04%6.74B USD0.28%$41.85-2.49%
Vanguard U.S. Momentum Factor ETFVFMO1.93M0.10%1.9B USD0.13%$193.88-3.13%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Fidelity Enhanced Small Cap ETFFESM
Vanguard U.S. Momentum Factor ETFVFMOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.